Experts say we’re in a golden age for treating chronic kidney disease, with new drugs like Ozempic yielding major results.

A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.

CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.

Rilparencel, a percutaneous minimally invasive injectable product prepared from patients’ own kidney cells, is being developed to treat those with stage 3b or 4 CKD and either type 1 or type 2 ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window PHILADELPHIA -- ...

DALLAS — Jereme Peterson needed a miracle to happen after three years and ten hours a day on dialysis. The 42-year-old federal corrections officer had hit rock bottom with his weight at 315 pounds and ...

A mismatch between two common tests for kidney function may indicate a higher risk for kidney failure, heart disease, and ...

Record numbers of men and women globally are now estimated to have reduced kidney function, a new study shows. Figures rose ...